Ose Immunotherapeutics annual operating cash flow
2020
2021
2022
2023
2024
2025
Ose Immunotherapeutics Operating Cash Flow Growth & History (OSE)
Ose Immunotherapeutics's operating cash flow was −€34.0M for fiscal 2025.
View full Ose Immunotherapeutics company overviewOse Immunotherapeutics annual operating cash flow history
| Fiscal year | Period ended | Operating cash flow | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −€34.0M | −€82.5M | — |
| 2024 | 2024-12-31 | €48.4M | €68.2M | — |
| 2023 | 2023-12-31 | −€19.8M | −€1.5M | — |
| 2022 | 2022-12-31 | −€18.3M | −€8.3M | — |
| 2021 | 2021-12-31 | −€9.9M | €9.6M | — |
| 2020 | 2020-12-31 | −€19.6M | — | — |
Ose Immunotherapeutics operating cash flow trends
Over the last five fiscal years, Ose Immunotherapeutics's operating cash flow decreased from −€19.6M to −€34.0M, a change of −€14.5M.
About the metric
What operating cash flow means
Operating cash flow is the cash generated or used by a company’s core operations. It incorporates working-capital movements and other operating cash items, and it is the starting point for calculating free cash flow.
Calculation and source
reported operating cash flow
TickerStat standardizes net cash provided by or used in operating activities reported in company official filings. It is historical filing data before capital expenditures, financing activities, and investing activities. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ose Immunotherapeutics source filings ↗